Innate Pharma (IPHA) Intangibles (2017 - 2024)

Innate Pharma (IPHA) has reported Intangibles for 8 consecutive years, with $135416.6 the latest figure, recorded in Q2 2024.

• Quarterly Intangibles fell 86.82% year-over-year to $135416.6 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $135416.6 (down 86.82% YoY) and the FY2023 annual result came in at $473389.0, down 73.26% from the prior year.
• Intangibles retreated to $135416.6 in Q2 2024 per IPHA's latest filing, from $473389.0 in the prior quarter.
• Over the last five years, Intangibles for IPHA reached as high as $95.2 billion in Q2 2020 and fell as low as $135416.6 in Q2 2024.
• A 5-year average of $10.6 billion and a median of $49.2 million in 2022 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2021 — Intangibles sank 99.95% — and 2022, when it dropped 4.28%.
• Year by year, Intangibles stood at $52.7 million in 2020, then fell by 4.53% to $50.3 million in 2021, then sank by 96.48% to $1.8 million in 2022, then plunged by 73.26% to $473389.0 in 2023, then plunged by 71.39% to $135416.6 in 2024.
• According to Business Quant data, Intangibles over the past three periods registered $135416.6, $473389.0, and $1.0 million for Q2 2024, Q4 2023, and Q2 2023 respectively.